Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DOCETAXEL | Accord Healthcare | N-201195 RX | 2012-04-20 | 3 products, RLD, RS |
DOCETAXEL | Allergan | N-203551 RX | 2013-04-12 | 4 products |
DOCETAXEL | Hospira | N-022234 RX | 2011-03-08 | 6 products, RLD, RS |
DOCETAXEL | Sandoz | N-201525 RX | 2011-06-29 | 3 products |
TAXOTERE | Sanofi | N-020449 RX | 2010-08-02 | 3 products, RLD, RS |
DOCETAXEL | Shilpa Medicare | N-205934 RX | 2015-12-22 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
beizray | New Drug Application | 2024-11-04 |
docetaxel | New Drug Application | 2025-01-31 |
docetaxel anhydrous | ANDA | 2023-07-10 |
docivyx | New Drug Application | 2024-07-03 |
Code | Description |
---|---|
J9171 | Injection, docetaxel, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | 2 | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 4 | 4 | — | — | 9 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | 4 | — | — | 6 |
Esophageal neoplasms | D004938 | — | C15 | — | — | 2 | — | 1 | 3 |
Neutropenia | D009503 | — | D70 | — | 1 | 2 | — | — | 3 |
Febrile neutropenia | D064147 | — | — | — | 1 | 2 | — | — | 3 |
Carcinoma | D002277 | — | C80.0 | — | 2 | 1 | — | — | 3 |
Squamous cell carcinoma | D002294 | — | — | — | 2 | 1 | — | — | 3 |
Adenocarcinoma | D000230 | — | — | 2 | — | 1 | — | — | 3 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | — | — | — | 3 |
Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 2 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
Neoadjuvant therapy | D020360 | — | — | — | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Esophageal squamous cell carcinoma | D000077277 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma of lung | D000077192 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Docetaxel |
INN | docetaxel |
Description | Docetaxel anhydrous is a tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group. It has a role as an antineoplastic agent, a photosensitizing agent and an antimalarial. It is a tetracyclic diterpenoid and a secondary alpha-hydroxy ketone. It derives from a hydride of a taxane. |
Classification | Small molecule |
Drug class | antineoplastics, taxane derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O |
PDB | — |
CAS-ID | 148408-66-6 |
RxCUI | — |
ChEMBL ID | CHEMBL3545252 |
ChEBI ID | 59809 |
PubChem CID | 148124 |
DrugBank | DB01248 |
UNII ID | 699121PHCA (ChemIDplus, GSRS) |